A new Harris Interactive poll shows a majority of American parents believe they, rather than the government, should have the final say in which vaccines their children receive.
A new Harris Interactive poll shows a majority of American parents believe they, rather than the government, should have the final say in which vaccines their children receive.
The poll, commissioned by the Center for Personal Rights, queried a representative sample of American parents about vaccination. The survey was conducted online in May within the United States by Harris Interactive on behalf of the Center for Personal Rights, Inc., among 1,144 parents of children age 17 years or younger.
Poll results indicate a majority of American parents, 52%, believe that "parents should have the right to decide which vaccines their children receive without government mandates."
Such results may stem from recent media reports, which have since been discredited, that vaccines do more harm than good, may cause autism, or are no longer necessary for certain diseases.
“In one warning after another, vaccine opponents often exaggerate or even make up immunization risks, with no scientific evidence to support their claims,” according to a statement on the American Academy of Pediatrics website. “They may imply that vaccines aren’t effective. At the same time, they downplay or don’t discuss the serious diseases that vaccines can eliminate or reduce in frequency. No wonder some parents are left feeling anxious and, in some cases, keep their youngster unvaccinated at the risk of their child’s health.”
But those assurances may be falling on deaf ears. Other results from the Center for Personal Rights, Inc. research include:
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Roflumilast Foam Showed Strong Results for Scalp and Body Psoriasis in Teens and Adults
May 7th 2025A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.
Read More